🌅 Pre-Market Pulse

S&P Futures 7,421.25 ▼ -22.75 (-0.31%)	Nasdaq Futures 29,235.25 ▼ -126.50 (-0.43%)	Dow Futures 49,932.00 ▼ -90.00 (-0.18%)
10Y Treasury 4.57% ▼ -0.09%	US Dollar 99.27 ▲ +0.07 (+0.08%)	Bitcoin $77,139 ▼ -$337 (-0.44%)

Good morning! It is Thursday, May 21, 2026, and futures are pointing modestly lower to start the session, with the S&P 500 off about a third of a percent and the Nasdaq slipping 0.43% in pre-market trade. The red ink, though, is sharing the spotlight with some genuinely headline-grabbing news out of pharma, tech, and Washington. Here is your morning rundown.

👀 What to Watch Today

Today's session carries a few things worth circling on the radar. Eli Lilly (LLY) is the name everyone will be tracking after its retatrutide trial data dropped overnight, and any analyst commentary or price target adjustments throughout the morning could keep the stock moving. The obesity drug space has a way of lifting the entire sector when a headline this big hits.

On the macro side, Treasury yields are actually pulling back this morning, with the 10-year sitting at 4.57% and the 30-year at 5.12%. That modest bond rally could provide some cushion for equities if it holds through the session. Watch how rate-sensitive sectors like utilities and real estate respond at the open.

The dollar index (DXY) is hanging just above 99 at 99.27, a small uptick that could create mild headwinds for multinational earnings plays. Bitcoin is also slightly in the red at $77,139, so the risk-off tone is broad but not panicked heading into today's open.

This NEW Fuel Will Kill Nuclear Power [ad]

🌏 Overnight Recap

While US markets were closed, the Trump administration made two significant moves that traders will be digesting all morning. First, the White House announced a $2 billion commitment to nine quantum computing companies, with the US government taking equity stakes in those firms. That is a meaningful shift in how Washington is engaging with emerging tech, and it has the quantum computing space lighting up in pre-market chatter.

The administration also unveiled plans for a major AI export financing program, offering billions in funding to encourage foreign buyers to choose American AI tools over foreign alternatives. The move is squarely aimed at extending US dominance in the global AI race, and companies with significant international AI revenue exposure are worth watching as details emerge.

In Europe, markets opened cautiously mixed as investors processed the US policy announcements. Asia closed with modest gains in Tokyo and a flat finish in Hong Kong, suggesting global sentiment is measured but not alarmed heading into New York's open.

Billionaire Warns "Civil Unrest" Coming [ad]

📊 Pre-Market Movers

Eli Lilly (LLY) is the clear pre-market standout this morning. The company's trial data for retatrutide showed patients losing more than 28% of their body weight over 18 months, a result that puts the drug in genuinely impressive territory. LLY shares are moving higher in pre-market trade, and the news could carry a halo effect into GLP-1 adjacent names like Novo Nordisk.

Advanced Micro Devices (AMD) is also in focus after announcing a commitment to invest over $10 billion into Taiwan's AI ecosystem. The move strengthens AMD's manufacturing and partnership infrastructure at a time when the AI chip race is as competitive as it has ever been. AMD shares are worth watching closely at the open given the scale of the announcement.

Bayer's US-listed ADR (BAYRY) is getting a quiet but real lift from the FDA's decision to grant priority review status to finerenone for an additional indication. Priority review cuts the typical FDA decision timeline nearly in half, and that timeline compression matters a great deal to pharma investors.

The "Safe" Stock That Could Destroy You [ad]

🔍 Today's Watchlist

1. LLY: Retatrutide trial results show 28% weight loss in 18 months, a potential blockbuster catalyst
2. AMD: $10B Taiwan AI investment commitment could move the stock and ripple through the chip sector
3. Quantum computing names: $2B in US government funding with equity stakes is a sector-wide catalyst
4. 10-Year Treasury at 4.57%: A continued yield pullback could support growth stocks through the session
5. BAYRY / BAYZF: Bayer's finerenone scores FDA priority review, a meaningful regulatory milestone to watch

🎯 The Morning Playbook

The setup today is a market under mild pressure from the futures side, but with a surprisingly rich set of individual stock catalysts to trade around. LLY is the single biggest story, and it could pull healthcare broadly higher even if the broader indexes struggle to find traction. AMD and the quantum names give the tech side its own idiosyncratic fuel to work with.

The bond market is actually cooperating a bit this morning, and if yields continue their modest retreat, that could soften the blow from the futures decline. Keep an eye on whether growth names use the lower-rate backdrop as cover to outperform even on a down tape.

Not every morning needs a clean directional read, and today is one where the sector rotation story may matter more than the index level. Follow the news flow, watch LLY and AMD closely, and remember that a flat or slightly negative open does not preclude some genuinely interesting moves underneath the surface.

Make this 1 trade on Friday at 2:59pm [ad]